CapsoVision (NASDAQ:CV) Issues Quarterly Earnings Results

CapsoVision (NASDAQ:CV) issued its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $3.64 million during the quarter.

Here are the key takeaways from CapsoVision’s conference call:

• Commercial momentum continued: Q2 revenue rose 10% year over year to $3.6 million, while CapsoCam Plus capsule shipments increased 13% and total patients imaged reached more than 176,000. Management also cited customer renewals and growing adoption among large hospital systems and GI networks.
• AI Highlights launched internationally and is expected to support physician efficiency and broader platform adoption. The company anticipates FDA clearance by the end of Q3 and a U.S. launch shortly thereafter, although management cautioned that clearance is not guaranteed.
• Gross margin declined to 51% from 55% a year ago because of competitive pricing pressure and higher inbound customs and tariff costs. Operating expenses also increased substantially to $9.5 million, driven by clinical and product development investments, public-company costs, and stock-based compensation.
• The CapsoCam Colon FDA submission was pushed back one quarter to Q4 2026 because the company needs additional positive subjects with significant polyps, increasing development and timing risk despite management’s confidence in the second-generation platform.
• Management expects second-half 2026 revenue to exceed first-half revenue, with Q4 typically the strongest quarter due to seasonality. The company ended Q2 with $9.1 million in cash and has access to a $100 million at-the-market equity program, providing additional funding flexibility.

CapsoVision Stock Down 2.5%

Shares of NASDAQ CV traded down $0.17 during midday trading on Friday, hitting $6.62. The stock had a trading volume of 83,286 shares, compared to its average volume of 257,206. CapsoVision has a 1-year low of $3.43 and a 1-year high of $15.37. The company has a market capitalization of $330.64 million and a price-to-earnings ratio of -2.83. The company has a fifty day moving average price of $6.78 and a 200 day moving average price of $6.33.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Insider Transactions at CapsoVision

In other CapsoVision news, major shareholder Eliyahou Et Al Harari purchased 61,068 shares of the business’s stock in a transaction that occurred on Friday, July 17th. The shares were purchased at an average price of $6.73 per share, for a total transaction of $410,987.64. Following the completion of the acquisition, the insider owned 3,343,119 shares of the company’s stock, valued at approximately $22,499,190.87. This represents a 1.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 156,218 shares of company stock worth $1,007,902. 2.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CapsoVision

Several large investors have recently made changes to their positions in CV. Wells Fargo & Company MN lifted its holdings in shares of CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after acquiring an additional 2,508 shares in the last quarter. Legal & General Group Plc acquired a new position in CapsoVision during the 2nd quarter worth approximately $26,000. Deutsche Bank AG purchased a new position in CapsoVision in the 4th quarter worth approximately $47,000. Virtu Financial LLC acquired a new stake in CapsoVision in the fourth quarter valued at approximately $128,000. Finally, Millennium Management LLC acquired a new stake in CapsoVision in the fourth quarter valued at approximately $163,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.